A prospective, randomized, double-blind study comparing the efficacy and safety of type a botulinum toxins botox and prosigne in the treatment of cervical dystonia.

Abstract:

:Botulinum toxin A (BTA) is considered an effective treatment of cervical dystonia. The aim of this prospective, randomized, double-blind study was to compare Botox and Prosigne, a BTA of Chinese origin, with a view to establish the safety, the efficacy, and the equivalence of doses of the 2 formulations in the treatment of cervical dystonia. Twenty-four patients were randomized to receive 300 U of Botox or Prosigne (12 patients in each group). The patients were assessed before the injection and after 4 and 16 weeks by the Toronto Western Spasmodic Torticollis Rating Scale and the Short-Form 36 for quality of life before and 16 weeks after the injection. All patients were comparable in age, time since onset, number of previous injections, and time since last BTA application. According to the Toronto Western Spasmodic Torticollis Rating Scale scores, the patients improved after injection and the scores increased after 16 weeks, without returning to baseline values. Both pain and burning during the injection and the treatment outcomes were similar in both groups. No systemic adverse events occurred, and the severity and frequency of local events were comparable in both groups. Average duration of effect was similar in both groups (11 weeks). The quality-of-life evaluations before and after the injections were comparable in both groups. Social aspects, pain, and vitality improved after 16 weeks in both groups. In conclusion, Botox and Prosigne were determined to have equivalent efficacy, safety, and tolerability profiles and dose equivalence for cervical dystonia treatment is 1:1.

journal_name

Clin Neuropharmacol

authors

Quagliato EM,Carelli EF,Viana MA

doi

10.1097/WNF.0b013e3181c46f48

subject

Has Abstract

pub_date

2010-01-01 00:00:00

pages

22-6

issue

1

eissn

0362-5664

issn

1537-162X

journal_volume

33

pub_type

临床试验,杂志文章,随机对照试验
  • Acute spinal cord injury, part I: pathophysiologic mechanisms.

    abstract::Spinal cord injury (SCI) is a devastating and common neurologic disorder that has profound influences on modern society from physical, psychosocial, and socioeconomic perspectives. Accordingly, the present decade has been labeled the Decade of the Spine to emphasize the importance of SCI and other spinal disorders. Sp...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00002826-200109000-00002

    authors: Dumont RJ,Okonkwo DO,Verma S,Hurlbert RJ,Boulos PT,Ellegala DB,Dumont AS

    更新日期:2001-09-01 00:00:00

  • Effects of terguride on anterior pituitary function in parkinsonian patients treated with L-dopa: a double-blind study versus placebo.

    abstract::In a randomized double-blind study, 20 parkinsonian patients (suffering from the disease for 2-18 years), chronically treated with levodopa (500-750 mg/day for 0.5-12 years), received terguride (1 mg b.i.d.) or placebo for 4 weeks. Growth hormone (GH), prolactin (PRL), thyroid-stimulating hormone (TSH), and insulin-li...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00002826-199619010-00006

    authors: Martignoni E,Horowski R,Liuzzi A,Costa A,Dallabonzana D,Cozzi R,Attanasio R,Rainer E,Nappi G

    更新日期:1996-02-01 00:00:00

  • Pharmacokinetic considerations for the use of levodopa in the treatment of Parkinson disease: focus on levodopa/carbidopa/entacapone for treatment of levodopa-associated motor complications.

    abstract::Parkinson disease (PD) is a progressive, disabling, neurodegenerative disorder characterized by both motor and nonmotor symptoms. Monoamine oxidase B inhibitors, dopamine agonists, N-methyl-D-aspartate antagonists and levodopa (LD), with its various formulations and administration modes, mainly improve the motor sympt...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/WNF.0b013e31828f3385

    authors: Müller T

    更新日期:2013-05-01 00:00:00

  • Reboxetine addition in patients with mirtazapine-resistant depression: a case series.

    abstract:OBJECTIVES:Treatment-resistant depression is a common occurrence in clinical practice as well as combination treatment with 2 different antidepressants. In the present case series, we study the effectiveness of the addition of reboxetine, during 12 weeks, to 14 outpatients diagnosed with major depressive disorder, acco...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/01.WNF.0000228211.19818.14

    authors: López-Muñoz F,Rubio G,Alamo C,García-García P,Pardo A

    更新日期:2006-07-01 00:00:00

  • Hypothermia induced by atypical neuroleptics.

    abstract::Hypothermia is a potentially life-threatening emergency. This article examines the case of a 34-year-old, mentally retarded man who experienced three episodes of hypothermia during recurrent exposure to pipamperone. After the pipamperone dose was largely reduced, no further hypothermic episodes occurred. Nine other ca...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:

    authors: Schwaninger M,Weisbrod M,Schwab S,Schröder M,Hacke W

    更新日期:1998-11-01 00:00:00

  • Rare neurodevelopmental abnormalities of sarcosinemia may involve glycinergic stimulation of a primed N-methyl-d-aspartate receptor.

    abstract::Sarcosinemia is a relatively rare autosomal recessive disorder that has a varied phenotypic presentation; rarely, it is associated with neurodevelopmental and neurological abnormalities. Sarcosine is a key intermediate in 1-carbon metabolism, and its elevation in blood and urine could reflect a deficient pool size of ...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/01.WNF.0000236767.46526.1F

    authors: Deutsch SI,Rosse RB,Long KD,Gaskins B,Mastropaolo J

    更新日期:2006-11-01 00:00:00

  • L-tyrosine pharmacotherapy of schizophrenia: preliminary data.

    abstract::The utility of L-tyrosine (10 g/day in four divided doses) as an adjuvant to molindone (150 mg/day) in the treatment of schizophrenia was investigated using a placebo-controlled, double-blind crossover design (3 weeks on L-tyrosine, 3 weeks on placebo). The objective of this inpatient study was to increase dopaminergi...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00002826-199402000-00006

    authors: Deutsch SI,Rosse RB,Schwartz BL,Banay-Schwartz M,McCarthy MF,Johri SK

    更新日期:1994-02-01 00:00:00

  • The effect of catechol-O-methyl transferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers.

    abstract::We studied the effect of inhibiting the enzyme catechol-O-methyltransferase (COMT) by a novel COMT inhibitor, entacapone, on the pharmacokinetics and metabolism of levodopa in 12 healthy male volunteers. Single increasing oral doses of entacapone (50-400 mg) were administered concomitantly with a single oral dose of l...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-199304000-00007

    authors: Keränen T,Gordin A,Harjola VP,Karlsson M,Korpela K,Pentikäinen PJ,Rita H,Seppälä L,Wikberg T

    更新日期:1993-04-01 00:00:00

  • Effects of carbamazepine on prolactin secretion in normal subjects and in epileptic subjects.

    abstract::The effects of carbamazepine (CBZ) on spontaneous secretion of prolactin (PRL) and after stimulation with thyrotropin releasing hormone (TRH) were evaluated. Volunteer subjects after acute CBZ administration, and epileptic subjects with complex partial seizures chronically treated with CBZ, were examined. In an epilep...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-198506000-00006

    authors: Bonuccelli U,Murialdo G,Martino E,Lecchini S,Bonura ML,Bambini G,Murri L

    更新日期:1985-01-01 00:00:00

  • Fulminant CNS perivascular lymphocytic proliferation: association with sargramostim, a hematopoietic growth factor.

    abstract::Sargramostim (GM-CSF) therapy was instituted in a 49-year-old woman with hepatitis C on chronic interferon alpha-2b therapy. Within two weeks, she developed progressive confusion, lethargy, and gait disturbance. At autopsy 4 months later, diffuse perivascular nonmonoclonal lymphoid infiltrates were demonstrated throug...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:

    authors: Riggs JE,Mansmann PT,Cook LL,Schochet SS Jr,Hogg JP

    更新日期:1999-09-01 00:00:00

  • Efficacy of clobazam as add-on therapy for refractory epilepsy: experience at a US epilepsy center.

    abstract:RATIONALE:Clobazam (CLB) has proven efficacy against multiple seizure types. Although available in many countries, it is not approved by the US Food and Drug Administration. The objective of this study was to evaluate the usage patterns, efficacy, tolerability, and 1-year retention of CLB in patients with refractory ep...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0b013e31815cd960

    authors: Montenegro MA,Arif H,Nahm EA,Resor SR Jr,Hirsch LJ

    更新日期:2008-11-01 00:00:00

  • Pharmacological mechanisms of opioid analgesics.

    abstract::The description of multiple classes of opioid receptors has had a major impact on our understanding of the mechanisms of analgesia. Three major classes of opioid receptors have been defined: mu, kappa, and delta. The mu receptors have been further subclassified into two distinct subtypes (mu 1 and mu 2), as have the d...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00002826-199302000-00001

    authors: Pasternak GW

    更新日期:1993-02-01 00:00:00

  • Medical treatment of patients with infantile spasms.

    abstract::Infantile spasms are the main feature in West syndrome, an age-related epilepsy syndrome that affects 1 in every 2,000-4,000 infants. The authors provide a comprehensive review of the literature about infantile spasms and their therapy. In the United States, the drug of choice for infantile spasms, at least the crypto...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00002826-200203000-00001

    authors: Mikati MA,Lepejian GA,Holmes GL

    更新日期:2002-03-01 00:00:00

  • Pharmacokinetics and pharmacodynamics of L-Dopa after acute and 6-week tolcapone administration in patients with Parkinson's disease.

    abstract::Tolcapone, a central and peripheral catechol O-methyltransferase (COMT) inhibitor, reduces the conversion of L-Dopa into 3-O-methyl-Dopa (3-OMD), thus leading to more stable and sustained L-Dopa plasma levels. This study was designed to evaluate the effects of acute and 6-week tolcapone administration on L-Dopa pharma...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-199901000-00005

    authors: Napolitano A,Del Dotto P,Petrozzi L,Dell'Agnello G,Bellini G,Gambaccini G,Bonuccelli U

    更新日期:1999-01-01 00:00:00

  • Cytosolic and nuclear sex steroid receptors in meningioma.

    abstract::To determine the nature of the hormone dependency of meningioma, particularly whether progestin receptor (PR) and tumor growth are estrogen-dependent, we measured the cytosol estrogen receptor (ER) and PR separately by an exchange assay with [3H]R 2858 (for ER) and [3H]RU 27987 (for PR) in 21 meningiomas. We correlate...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-198412000-00018

    authors: Moguilewsky M,Pertuiset BF,Verzat C,Philibert D,Philippon J,Poisson M

    更新日期:1984-01-01 00:00:00

  • Brain monoamine output alterations after a single venlafaxine challenge in experimental hepatic encephalopathy.

    abstract::Venlafaxine (VEN) pharmacokinetics and effects on the brain monoamine output were investigated in the context of experimental hepatic encephalopathy (HE). Systemic VEN (10 mg/kg; subcutaneous) was administered to chronic portacaval shunted (PCS) and sham-operated rats. Their neocortical extracellular levels of 5-HT, 5...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:

    authors: Wikell C,Bergqvist PB,Hjorth S,Apelqvist G,Björk H,Bengtsson F

    更新日期:1998-09-01 00:00:00

  • Methylphenidate-Induced Enuresis: 3 Case Reports.

    abstract:ABSTRACT:Attention-deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental disorder in children and adolescents. Methylphenidate (MPH) is one of the most widely used drugs in the treatment of ADHD. Enuresis can occur comorbidly with ADHD. However, enuresis is sometimes seen in patients with ADHD as an adve...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0000000000000422

    authors: Uzun N,Akinci MA,Karatoprak S

    更新日期:2021-01-01 00:00:00

  • Early addition of selegiline to L-Dopa treatment is beneficial for patients with Parkinson disease.

    abstract:OBJECTIVES:To evaluate the clinical outcome of Parkinson disease (PD) patients treated with selegiline (with L-Dopa/decarboxylase inhibitor) in the early stage of the disease in comparison with that of late-stage use of selegiline. METHODS:The study and the reference groups were extracted from a large database of the ...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0b013e3181bbf45c

    authors: Mizuno Y,Kondo T,Kuno S,Nomoto M,Yanagisawa N

    更新日期:2010-01-01 00:00:00

  • One-Year Retention Study of Adjunctive Perampanel Treatment in Epilepsy Patients.

    abstract:OBJECTIVES:Perampanel is a recently introduced antiepileptic drug (AED) with a unique action mechanism of noncompetitive and selective α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid antagonist. Because of delayed approval of perampanel in most Asian countries, there is limited information on the clinical usefulne...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0000000000000255

    authors: Kim DW,Oh J

    更新日期:2018-01-01 00:00:00

  • A trial of D-cycloserine to treat stereotypies in older adolescents and young adults with autism spectrum disorder.

    abstract:OBJECTIVES:Autism spectrum disorders (ASDs) have core impairments in social communication as well as the presence of repetitive, stereotypic behaviors and restricted interests. Older adolescents and young adults are particularly impacted by these deficits. Preclinical data implicate glutamatergic dysfunction in the pat...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1097/WNF.0000000000000033

    authors: Urbano M,Okwara L,Manser P,Hartmann K,Herndon A,Deutsch SI

    更新日期:2014-05-01 00:00:00

  • First clinical evaluation of ganstigmine in patients with probable Alzheimer's disease.

    abstract::The objective of this study was to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of five fixed doses of ganstigmine (CHF 2819) in patients with probable Alzheimer's disease (AD). This randomized, double-blind, placebo-controlled trial evaluated five dose levels (5, 7...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00002826-200305000-00011

    authors: Jhee SS,Fabbri L,Piccinno A,Monici P,Moran S,Zarotsky V,Tan EY,Frackiewicz EJ,Shiovitz T

    更新日期:2003-05-01 00:00:00

  • The use of aminopyridines in neurological disorders.

    abstract::Aminopyridines are members of a family of monoamino and diamino derivatives of pyridine, and their principal mechanism of action is dose-dependent blockade of voltage-gated potassium channels, in particular, fast voltage-gated potassium channels. To date, only 2 main broad-spectrum potassium channel blockers, 4-aminop...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/WNF.0b013e31825a68c5

    authors: Sedehizadeh S,Keogh M,Maddison P

    更新日期:2012-07-01 00:00:00

  • Seizure control after chronic pharmacotherapy in epileptic disorders beginning after 40 years of age.

    abstract::Few studies have been published on the pharmacologic response to treatment of patients whose seizures begin after 40 years of age. The purpose of this study was to assess the impact of chronic pharmacotherapy on the seizure control of such patients. We retrospectively studied the seizure frequency recorded during a 12...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-199502000-00002

    authors: Hasegawa H,Kanner AM

    更新日期:1995-02-01 00:00:00

  • Neutropenia as a complication of high-dose intravenous immunoglobulin therapy in adult patients with neuroimmunologic disorders.

    abstract::To investigate clinical aspects of the neutropenia induced by high-dose intravenous immunoglobulin therapy (IVIG) we performed serial hematology, including differentiation of white blood cells (WBC), before and after 22 instances of IVIG in 16 patients with neuroimmunologic disorders. WBC and neutrophils showed a sign...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-200311000-00009

    authors: Matsuda M,Hosoda W,Sekijima Y,Hoshi K,Hashimoto T,Itoh S,Ikeda S

    更新日期:2003-11-01 00:00:00

  • Levodopa efficacy and pathological basis of Parkinson syndrome.

    abstract::Levodopa is the most effective drug for symptomatic control of Parkinson syndrome (PS). We report a 22-year clinicopathological study of 59 PS cases. Of the entire group, 37 (63%) had an adequate trial on levodopa. Some improvement was noted on that drug in 24 (65%) cases. Improvement was seen in 94% of idiopathic Par...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-199012000-00007

    authors: Rajput AH,Rozdilsky B,Rajput A,Ang L

    更新日期:1990-12-01 00:00:00

  • Investigating the efficacy of paroxetine in developmental stuttering.

    abstract:OBJECTIVES:Paroxetine has been reported to be useful for management of stuttering symptoms, but only a few reports have examined its effects. We have investigated the efficacy of paroxetine in a randomized, placebo-controlled study. METHODS:Five stuttering subjects received paroxetine at 20 mg once daily at night for ...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1097/WNF.0b013e31819817eb

    authors: Busan P,Battaglini PP,Borelli M,Evaristo P,Monti F,Pelamatti G

    更新日期:2009-07-01 00:00:00

  • Piracetam in the treatment of different types of myoclonus.

    abstract::Forty patients with different clinical and electrophysiological types of myoclonus were treated with piracetam (18-24 g per day, p.o.) alone, or with other drugs (clonazepam, sodium valproate, and primidone) in different combinations. Piracetam in monotherapy improved the electrophysiological abnormalities in patients...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-198812000-00006

    authors: Obeso JA,Artieda J,Quinn N,Rothwell JC,Luquin MR,Vaamonde J,Marsden CD

    更新日期:1988-12-01 00:00:00

  • The emergence of devastating impulse control disorders during dopamine agonist therapy of the restless legs syndrome.

    abstract:INTRODUCTION:The Restless Legs Syndrome is a common sensorimotor disorder, typically amenable to treatment with dopamine agonist therapy. Dopamine agonists have been associated with emergent impulse control disorders (ICDs) when used in patients with Parkinson disease, and ICDs have now been reported in individuals wit...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0b013e31820d6699

    authors: Dang D,Cunnington D,Swieca J

    更新日期:2011-03-01 00:00:00

  • Serotonin receptor subtypes: functional, physiological, and clinical correlates.

    abstract::The effects of 5-HT are varied and widely distributed throughout the human body. At this time, 5-HT research is a field ripe for "plucking." Not only is there a great demand for more selective agonists and antagonists, but there is more than enough work needed in receptor binding studies to keep pharmacologists employ...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:

    authors: Bonate PL

    更新日期:1991-02-01 00:00:00

  • Effects of tandospirone on "5-HT1A receptor-associated symptoms" in patients with Machado-Josephe disease: an open-label study.

    abstract:BACKGROUND:We investigated the frequencies of the symptoms such as "ataxia, depression, insomnia, anorexia, and pain," that have been reported to be associated with 5-HT1A receptor, and the effect of tandospirone citrate (tandospirone: 5-HT1A agonist) in patients with Machado-Joseph disease (MJD). METHODS:Ten MJD pati...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00002826-200401000-00005

    authors: Takei A,Fukazawa T,Hamada T,Sohma H,Yabe I,Sasaki H,Tashiro K

    更新日期:2004-01-01 00:00:00